Leadartis reaches a major milestone with the demonstration of absence of toxicity of its drug candidate in preclinical models

Leadartis reaches a major milestone with the demonstration of absence of toxicity of its drug candidate in preclinical models

Leadartis reaches a major milestone with the demonstration of absence of toxicity of its EGFR-targeted 4-1BB-agonistic bispecific Trimerbody which does not Induce Hepatotoxicity in transgenic mice with liver expression of human EGFR (https://www.frontiersin.org/articles/10.3389/fimmu.2020.614363/full).

These data support the role of FcγR interactions in the major off-tumor toxicities associated with IgG-based 4-1BB agonists and further validate the safety profile of EGFR-targeted Fc-less 4-1BB-agonistic trimerbodies in systemic cancer immunotherapy protocols. 

Share with

Start typing and press Enter to search